Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
RIVM launches new web-based version of ConsExpo An improved version of the computer program ConsExpo is now available via the RIVM website.
Assessment of health effects of alternative tobacco products To assess the effects on the health of users of alternative tobacco products, more knowledge is required about the composition of the product, the smoker’s behaviour (such as the amount of cigarett
Integrated approach reduces harmful effects of medicines in surface waters Residues of medicinal products, such as painkillers, hormones and antidepressants, are increasingly detected in surface water and drinking water.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
More tobacco products, number of additives stable In 2014, the number of tobacco products on the Dutch market increased to 4212. This is a 5 percent increase compared to 2013.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
Improving consumer exposure assessment to chemical substances By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co
Broad approach needed against pharmaceutical residues in environment We can all help to reduce pollution of the environment by pharmaceutical residues.